76.53
0.13 (0.17%)
| Previous Close | 76.40 |
| Open | 76.69 |
| Volume | 548,592 |
| Avg. Volume (3M) | 2,223,026 |
| Market Cap | 14,748,005,376 |
| Price / Sales | 39.56 |
| 52 Weeks Range | |
| Earnings Date | 19 Feb 2026 |
| Operating Margin (TTM) | -89.00% |
| Diluted EPS (TTM) | -3.56 |
| Quarterly Revenue Growth (YOY) | -44.80% |
| Current Ratio (MRQ) | 4.57 |
| Operating Cash Flow (TTM) | -500.42 M |
| Levered Free Cash Flow (TTM) | -261.20 M |
| Return on Assets (TTM) | -48.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | BridgeBio Pharma, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.13 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.97% |
| % Held by Institutions | 98.14% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 110.00 (Cantor Fitzgerald, 43.73%) | Buy |
| Median | 92.00 (20.21%) | |
| Low | 71.00 (Raymond James, -7.23%) | Buy |
| Average | 90.08 (17.71%) | |
| Total | 12 Buy | |
| Avg. Price @ Call | 66.03 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 06 Jan 2026 | 96.00 (25.44%) | Buy | 73.99 |
| Leerink Partners | 15 Dec 2025 | 86.00 (12.37%) | Buy | 74.51 |
| Bernstein | 11 Dec 2025 | 94.00 (22.83%) | Buy | 74.07 |
| Wells Fargo | 11 Nov 2025 | 84.00 (9.76%) | Buy | 66.58 |
| JP Morgan | 07 Nov 2025 | 77.00 (0.61%) | Buy | 61.80 |
| HC Wainwright & Co. | 03 Nov 2025 | 90.00 (17.60%) | Buy | 61.98 |
| 29 Oct 2025 | 90.00 (17.60%) | Buy | 66.62 | |
| Goldman Sachs | 31 Oct 2025 | 100.00 (30.67%) | Buy | 62.64 |
| Cantor Fitzgerald | 30 Oct 2025 | 110.00 (43.73%) | Buy | 63.37 |
| Piper Sandler | 30 Oct 2025 | 98.00 (28.05%) | Buy | 63.37 |
| Raymond James | 30 Oct 2025 | 71.00 (-7.23%) | Buy | 63.37 |
| 21 Oct 2025 | 59.00 (-22.91%) | Buy | 54.36 | |
| TD Cowen | 30 Oct 2025 | 95.00 (24.13%) | Buy | 63.37 |
| Truist Securities | 30 Oct 2025 | 80.00 (4.53%) | Buy | 63.37 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |